Genetic analysis of influenza B viruses isolated in Uganda during the 2009–2010 seasons

Byarugaba, Denis K.; Erima, Bernard; Millard, Monica; Kibuuka, Hannah; Lukwago, Luswa; Bwogi, Josephine; Mimbe, Derrick; Mworozi, Edison; Sharp, Bridget; Krauss, Scott; Webby, Richard J.; Webster, Robert G.; Martin, Samuel K.; Wâbwire-Mângen, Fred; Ducatez, Mariette

doi:10.1186/1743-422x-10-11

Cited by 15 publications

(18 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Trivalent influenza vaccines recommended for immunization against influenza contain the two A-strains (H1N1 and H3N2) but only one B-strain selected each year in the Yamagata-like lineage group or the Victoria-like one [9,29]. The efficacy and effectiveness of influenza vaccines depend on the degree of similarity between the circulating viruses and those included in the vaccine [12].…”

Section: Discussionmentioning

confidence: 99%

“…Current seasonal influenza vaccines include the two A-strains (H1N1 and H3N2) but only one B-strain [9]. The prediction for which B-strain to include in the vaccine is not always accurate [6], giving rise to a variable level of mismatch between the B-strain contained in the vaccine and the B-strain causing infection and disease each season.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults

et al. 2013

View full text Add to dashboard Cite

BackgroundTwo phylogenetic lineages of influenza B virus coexist and circulate in the human population (B/Yamagata and B/Victoria) but only one B-strain is included in each seasonal vaccine. Mismatch regularly occurs between the recommended and circulating B-strain. Inclusion of both lineages in vaccines may offer better protection against influenza.MethodsThis study (NCT00714285) assessed the immunogenicity and safety of two candidate quadrivalent influenza vaccines (QIV) containing two A- and two B-strains (one from each lineage) in adults (18–60 years). Subjects were randomized and stratified by age to receive either QIV (non-adjuvanted or low-dose adjuvanted [LD QIV-AS]) or trivalent influenza vaccine (TIV, non-adjuvanted or low-dose adjuvanted [LD TIV-AS]), N = 105 in all treatment groups. The study evaluated the statistical non-inferiority of the immunological response elicited by QIV and LD QIV-AS versus TIV and LD TIV-AS and the statistical superiority of the response elicited by the quadrivalent vaccines against the B-strain (B/Jiangsu) not included in the TIV.ResultsPre-defined non-inferiority and superiority criteria were reached for both QIVs compared to the TIVs. On Day 21 in all vaccine groups SCRs were ≥54.8%, SPRs ≥88.5% and SCFs ≥5.4 for the A strains and B strain included in all vaccines (B/Malaysia). This fulfilled the European (CHMP) and the US (CBER) licensing criteria for the assessment of influenza vaccines in adults (CHMP criteria: SCR > 40%, SPR > 70%, SCF > 2; CBER criteria: LL of 95% CI for SPR ≥ 70% or SCR ≥ 40%). Only the QIVs met the CHMP and CBER criteria for the B/Jiangsu strain. In the QIV and LD-QIV-AS groups, the SCFs were 9.1 and 8.1, respectively and the SPRs were 98.1% and 95.2%, whereas for the TIV and LD-TIV-AS groups, the SCFs were 2.3 and 2.5, respectively, and the SPRs were 75.0% and 63.8%, with the LLs of the 95% CI <70% for SPR and <40% for SCR.ConclusionsAddition of a fourth strain did not impact the immune response elicited by the three original strains contained in the TIV. A clear immunological benefit was seen with the QIV formulation for the second B-strain, indicating that quadrivalent vaccines could provide broader protection against influenza.Trial registrationClinicalTrials.gov: NCT00714285

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults

et al. 2013

View full text Add to dashboard Cite

show abstract

“…For several decades now, these two lineages have been co‐circulating. Based on the nucleotide phylogenetic analysis of the HA gene, several groupings of type B influenza virus have been identified: B/Victoria lineage viruses are sub‐divided into six clades (clade 1‐6), and B/Yamagata lineage viruses are sub‐divided into three clades (clade 1‐3) . For a decade now, most viruses of the B/Victoria lineage have been described belonging to the genetic clade 1 represented by the vaccine strain, B/Brisbane/60/2008 .…”

Section: Introductionmentioning

confidence: 99%

“…Based on the nucleotide phylogenetic analysis of the HA gene, several groupings of type B influenza virus have been identified: B/Victoria lineage viruses are sub‐divided into six clades (clade 1‐6), and B/Yamagata lineage viruses are sub‐divided into three clades (clade 1‐3) . For a decade now, most viruses of the B/Victoria lineage have been described belonging to the genetic clade 1 represented by the vaccine strain, B/Brisbane/60/2008 . The majority of B/Yamagata lineage viruses, on the other hand, have been distributed into two main clades: Yamagata clade‐2, represented by B/Massachusetts/2/2012, and Yamagata clade‐3, represented by B/Wisconsin/01/2010 …”

Section: Introductionmentioning

confidence: 99%

Genetic characterization of influenza B virus in Cameroon and high frequency of reassortant strains

Monamele

Vernet

Njankouo

et al. 2018

Journal of Medical Virology

View full text Add to dashboard Cite

Influenza B is broadly divided into B/Victoria and B/Yamagata lineages based on its genetic and antigenic properties. We describe in this study the first report on genome characterization of type B influenza virus in the Cameroon National Influenza Center (NIC) between 2014 and 2017. Respiratory samples were collected as part of the influenza surveillance activity in the NIC. RNA products were tested for the presence of influenza using the CDC Influenza A/B typing panel. Thirty-five samples positive for influenza B were selected for sequencing three gene segments (HA, NA, and M) and phylogenetic trees were generated by MEGA version 6.0. Nucleotide phylogenetic analysis of the HA gene revealed the presence of three major clades among Cameroonian strains. All Victoria lineages grouped into B/Victoria clade 1A, while, Yamagata lineages grouped into Yamagata clade 2 (2014 strains) and Yamagata clade 3 (2015-2017). We observed a high frequency of reassortant viruses with Yamagata-like HA gene and Victoria-like NA gene (27.4%; 23/84). The results from this study confirm variations in the genome composition of type B influenza virus and emphasize on the relevance of molecular surveillance for spotting peculiar genetic variants of public health and clinical significance.

show abstract

“…Influenza B‐confirmed ARI samples were genotyped by Haemagglutinin ( HA ) gene sequencing using BigDye Terminator ver.3.1 cycle sequencing kit (Applied Biosystem, Foster City, CA, USA) with 3730 DNA Analyzer (Applied Biosystem, Foster City, CA, USA). Influenza B reference sequences including WHO recommended vaccine strains for northern hemisphere from 2007 to 2014 (https://www.who.int/influenza/vaccines/virus/recommendations/en/) were obtained from GenBank (http://www.ncbi.nlm.nih.gov/genbank/) and EpiFlu database within Global Initiative on Sharing All Influenza Data (GISAID)(http://platform.gisaid.org) and included in phylogenetic analysis as previously described . These reference strains were used in order to further classify lineage into groups based on Worldwide Influenza Centre (WIC) (https://www.crick.ac.uk/partnerships/worldwide-influenza-centre).…”

Section: Methodsmentioning

confidence: 99%

Influenza B associated paediatric acute respiratory infection hospitalization in central vietnam

Yoshihara

Toizumi

et al. 2019

Influenza Resp Viruses

View full text Add to dashboard Cite

Background Influenza B is one of the major etiologies for acute respiratory infections ( ARI ) among children worldwide; however, its clinical‐epidemiological information is limited. We aimed to investigate the hospitalization incidence and clinical‐epidemiological characteristics of influenza B‐associated paediatric ARI s in central Vietnam. Methods We collected clinical‐epidemiological information and nasopharyngeal swabs from ARI children hospitalized at Khanh Hoa General Hospital, Nha Trang, Vietnam from February 2007 through June 2013. Nasopharyngeal samples were screened for 13 respiratory viruses using Multiplex‐ PCR s. Influenza B‐confirmed cases were genotyped by Haemagglutinin gene sequencing. We analyzed the clinical‐epidemiological characteristics of influenza B Lineages (Victoria/Yamagata) and WHO Groups. Results In the pre‐A/H1N1pdm09 period, influenza B‐associated ARI hospitalization incidence among children under five was low, ranging between 14.7 and 80.7 per 100 000 population. The incidence increased to between 51.4 and 330 in the post‐A/H1N1pdm09. Influenza B ARI cases were slightly older with milder symptoms. Both Victoria and Yamagata lineages were detected before the A/H1N1pdm09 outbreak; however, Victoria lineage became predominant in 2010‐2013 (84% Victoria vs 16% Yamagata). Victoria and Yamagata lineages did not differ in demographic and clinical characteristics. In Victoria lineage, Group1 ARI cases were clinically more severe compared to Group5, presenting a greater proportion of wheeze, tachypnea, and lower respiratory tract infection. Conclusions The current results highlight the increased incidence of influenza B‐related ARI hospitalization among children in central Vietnam in the post‐A/H1N1pdm09 era. Furthermore, the difference in clinical severity between Victoria lineage Group1 and 5 implies the importance of influenza B genetic variation on clinical presentation.

show abstract

Genetic analysis of influenza B viruses isolated in Uganda during the 2009–2010 seasons

Cited by 15 publications

References 24 publications

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults

Genetic characterization of influenza B virus in Cameroon and high frequency of reassortant strains

Influenza B associated paediatric acute respiratory infection hospitalization in central vietnam

Contact Info

Product

Resources

About